Accretion Nutraveda Limited · BSE:ANL
Accretion Nutraveda — H1 FY2027 Earnings Presentation
28 slides from Accretion Nutraveda's earnings presentation, Nov 3, 2026
Slide 1: Cover letter to BSE for investor presentation
Date: 03rd November, 2026 To, Corporate Relations Department BSE Limited 25th Floor, P J Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 544694 Dear Sir/ Madam, Subject: Investors/ Analysts Presentation for the half year ended on 30th September, 2026 Pursuant to Regulation 30 of Securities
Slide 2: Investor Presentation H1 FY 2027
ACCRETION NUTRAVEDA LIMITED INVESTOR P R E S E N T AT I O N H1 FY 2027
Slide 3: Disclaimer
DISCLAIMER This presentation contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Accretion Nutraveda Limited (ANL) and its group companies’ future business developments and econo
Slide 4: Table of Contents
TABLE OF CONTENTS Company Overview Shareholding Overview Business Overview Industry Overview Financial Highlights Way Ahead
Slide 5: Company Overview
wy Accreti@n’ = Nutraveda Limited COMPANY OVERVIEW
Slide 6: Accretion Nutraveda Limited at a Glance
ACCRETION NUTRAVEDA LIMITED AT A GLANCE Science-Driven Nutrition | Wellness-Focused Growth Incorporated on 16th March 2021, Accretion Nutraveda Limited is engaged in the manufacturing of Ayurvedic, Nutraceutical and wellness products, catering to diverse healthcare and wellness needs through a portf
Slide 7: Public Listing – A New Chapter of Growth
PUBLIC LISTING – A NEW CHAPTER OF GROWTH Accretion Nutraveda Limited successfully launched its Initial Public Offering (IPO) in February 2026 and marked its debut on the BSE SME Platform of BSE Limited, reflecting a significant milestone in the Company’s growth journey. The IPO raised ₹ 24.77 crore
Slide 8: Key Milestones
KEY 2025 MILESTONES • Converted from Private Limited to Public Limited Company and renamed as “Accretion Nutraveda 2021 Limited” effective 02nd May, 2025 2026 • Achieved ISO 9001:2015 certification for Quality • Incorporated as “Accretion Nutraveda • Successfully listed on the BSE SME Management Sys
Slide 9: Shareholding Overview
N\ Accreti@n’ Nutraveda Limited SHAREHOLDING OVERVIEW
Slide 10: Shareholding Pattern as on 30th September 2026
SHAREHOLDING PATTERN AS ON 30th SEPTEMBER 2026 Script code of Company at BSE SME 544694 platform of BSE Limited (BSE SME) 30th September, 2026 Category of Investor No. of No. of Shares Held Holding (%) Shareholders Promoter & Promoter Group 10 5320000 73.48 % Public Holding 370 1920000 26.52 % Total
Slide 11: Business Overview
wy Accreti@n’ = Nutraveda Limited BUSINESS OVERVIEW
Slide 12: B.Pharm to BSE SME Platform of BSE Limited
BPHARM TO BSE SME PLATFORM OF BSE LIMITED United by a common vision and a strong foundation in Pharmacy Classroom, six B.Pharm college friends embarked on an entrepreneurial journey that led to the establishment of Accretion Nutraveda Limited. Through shared ambition, professional expertise and coll
Slide 13: Our Business Model
OUR BUSINESS MODEL Accretion Nutraveda Limited(ANL) follows a diversified business model encompassing CDMO Services, own-brand sales and exports, and product development and technology transfer. These business verticals support the Company’s manufacturing operations, market presence and opportunitie
Slide 14: Product by Dosage Forms
PRODUCT BY DOSAGE FORMS TA B L E T S CAPSULES ORAL EXTERNAL ORAL OILS LIQUIDS P R E PA R AT I O N S POWDER
Slide 15: Therapeutic Segment
THERAPEUTIC SEGMENT Brain, Memory & Neuron Care Aphrodisiac & Vitality Care UTI Care Digestive Care Cardiac Care Urinary Tract Care Liver Care Systemic & General Wellness Protein Supplements Baby Care Pediatric Care Pain Relief & Nasal Care Gastrointestinal (GIT) Care Single Herb Formulations Efferv
Slide 16: Advanced Manufacturing Infrastructure
ADVANCED MANUFACTURING INFRASTRUCTURE
Slide 17: Industry Overview
wy Accreti@n’ = Nutraveda Limited INDUSTRY OVERVIEW
Slide 18: India: Wellness & Nutraceutical Hub of the World
INDIA : WELLNESS & NUTRACEUTICAL HUB OF THE WORLD India's Nutraceutical Industry – A Fast- Growing Global Wellness Market Indian Nutraceutical Market (US$ Billion) Global Nutraceutical Market (US$ Billion) India's nutraceutical market is estimated at US$37–38 billion in 2026 and projected to reach U
Slide 19: CDMO Industry Overview
CDMO INDUSTRY OVERVIEW GLOBAL CDMO INDUSTRY INDIAN CDMO INDUSTRY Role & Importance of CDMOs End-to-end services from drug development to commercial production, helping pharma firms cut India’s CDMO manufacturing market is estimated to grow from USD costs, scale faster, and access advanced technologi
Slide 20: Financial Highlights
N\ Accreti@n’ Nutraveda Limited FINANCIAL HIGHLIGHTS
Slide 21: A Message from Our Leadership
A MESSAGE FROM OUR LEADERSHIP H1 FY 2026–27 has been an important period for Accretion Nutraveda Limited(ANL) as the Company continues to focus on Business expansion and operational efficiency. The Company Recorded revenue of ₹ 29.44 crore, representing a year-on-year growth of 109.35%. EBITDA stood
Slide 22: Performance Highlight (H1 FY 2027)
PERFORMANCE HIGHLIGHT (H1 FY 2027) TOTAL INCOME - ₹ 29.44 Cr (109.35% YoY) EBITDA - ₹ 6.26 Cr (88.03%% YoY) PAT - ₹ 4.73 Cr ( 98.66% YoY)
Slide 23: Profit and Loss Statement
PROFIT AND LOSS STATEMENT Particulars (₹ in Crore) H1 FY27 H1 FY26 YoY% H2 FY26 FY26 Total Income from 29.44 14.06 109.35% 19.54 33.6 Operations 0.16 FINANCIAL PERFORMANCE Other Income 0.00 0.11 0.11 Total Income 29.6 14.07 110.38% 19.65 33.71 HIGHLIGHTS Raw Materials 21.68 9.57 14.53 24.1 HI FY2027
Slide 24: Financial Highlights – Half Yearly (H1 FY27)
FINANCIAL HIGHLIGHTS – HALF YEARLY (HI FY27) Revenue (₹ Cr) EBITDA* (₹ Cr) / Margin (%) 7 23.7% 24% 6.3 6 24% 23% 29.4 5 23% 4 3.3 22% 3 21.3% 22% 14.06 2 21% 1 21% 0 20% H1 FY26 HI FY27 HI FY26 HI FY27 PAT (₹ Cr) / Margin (%) Net Worth (₹ Cr) 5 16.9% 4.7 17% 5 40.2 17% 4 4 17% 3 16% 2.4 3 2 16.1% 1
Slide 25: Financial Highlights – Annually (FY26)
FINANCIAL HIGHLIGHTS – ANNUALLY (FY26) Revenue (₹ Cr) EBITDA* (₹ Cr) / Margin (%) 8 27.2% 28.3% 30% 7.0 33.6 7 23.3% 25% 20.9% 6 20% 5 4 3.7 15% 16.0 3 10% 2 1.4 5.0 1 0.8 5% 2.9 0 0% FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 PAT (₹ Cr) / Margin (%) Net Worth (₹ Cr) 35.5 6 16.4% 18% 15.6% 15.1% 16% 5
Slide 26: The Way Ahead
N\ Accreti@n’ Nutraveda Limited THE WAY AHEAD
Slide 27: The Way Ahead
THE WAY AHEAD CAPEX The Company aims to enhance its manufacturing capabilities through the addition of leased premises adjacent to its existing facility, along with investments in machinery and equipment. The proposed expansion will focus on increasing production capacity, improving automation, stre
Slide 28: Thank You
THANK YOU. ACCRETION NUTRAVEDA LIMITED CS Payal Kotadiya Company Secretary & Compliance Officer E-mail: compliance@accretionnutraveda.com www.accretionnutraveda.com LISTED ON BSE SME PLATFORM
Accretion Nutraveda — H1 FY2027 Earnings Presentation on 6ix